FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up - Fulcrum Therapeutics ( NASDAQ:FULC ) , Axsome Therapeutics ( NASDAQ:AXSM )
Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its resubmitted new drug application ( NDA ) seeking approval for AXS-07 for the acute treatment of migraine. A final decision from the regulatory body is expected on Jan. 31, 2025.
| Ticker |
Sentiment |
Impact |
|
KRYS
|
Somewhat Bullish
|
30 %
|
|
JAZZ
|
Neutral
|
15 %
|
|
AXSM
|
Somewhat Bullish
|
23 %
|
|
FULC
|
Somewhat Bullish
|
30 %
|
